Skip to main content
Erschienen in: International Journal of Hematology 6/2013

01.12.2013 | Original Article

Excision repair cross-complementing group 2/Xeroderma pigmentousm complementation group D (ERCC2/XPD) genetic variations and susceptibility to diffuse large B cell lymphoma in Egypt

verfasst von: Mennat Allah Kamal El-Din, Mervat Mamdooh Khorshied, Zainab Ali El-Saadany, Marwa Ahmed El-Banna, Ola M. Reda Khorshid

Erschienen in: International Journal of Hematology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous neoplasm. Although several genetic and environmental factors have been postulated, no obvious risk factors have been emerged for DLBCL in the general population. DNA repair systems are responsible for maintaining the integrity of the genome and protecting it against genetic alterations that can lead to malignant transformation. The current study aimed at investigating the possible role of ERCC2/XPD Arg156Arg, Asp312Asn and Lys751Gln genetic polymorphisms as risk factors for DLBCL in Egypt. The study included 81 DLBCL patients and 100 healthy controls. Genotyping of the studied genetic polymorphisms was performed by polymerase chain reaction–restriction fragment length polymorphism technique. Our results revealed that there was no statistical difference encountered in the distribution of −Asp312Asn and −Lys751Gln polymorphic genotypes between DLBCL cases and controls, thus it could not considered as molecular risk factors for DLBCL in Egyptians. However, Arg156Arg polymorphism at exon-6 conferred twofold increased risk of DLBCL (OR 2.034, 95 %CI 1.015–4.35, p = 0.43), and the risk increased when co-inherited with Lys751Gln at exon-23 (OR 3.304, 95 %CI 1.113–9.812, p = 0.038). In conclusion, ERCC2/XPD Arg156Arg polymorphism might be considered as a genetic risk factor for DLBCL in Egyptians, whether alone or conjoined with Lys751Gln.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398–403.PubMedCrossRef Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398–403.PubMedCrossRef
2.
Zurück zum Zitat Hartge P, Smith MT. Environmental and behavioral factors and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(3):367–8.PubMedCrossRef Hartge P, Smith MT. Environmental and behavioral factors and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(3):367–8.PubMedCrossRef
3.
Zurück zum Zitat Worrillow L, Roman E, Adamson PJ, Kane E, Allan JM, Lightfoot TJ. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol. 2009;33(3–4):257–60.PubMedCrossRef Worrillow L, Roman E, Adamson PJ, Kane E, Allan JM, Lightfoot TJ. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol. 2009;33(3–4):257–60.PubMedCrossRef
4.
Zurück zum Zitat Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene. 2002;21:8949–56.PubMedCrossRef Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene. 2002;21:8949–56.PubMedCrossRef
5.
Zurück zum Zitat Shen M, Zheng T, Lan Q, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef Shen M, Zheng T, Lan Q, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef
6.
Zurück zum Zitat Smedby KE, Lindgren CM, Hjalgrim H, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15(2):258–65.PubMedCrossRef Smedby KE, Lindgren CM, Hjalgrim H, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15(2):258–65.PubMedCrossRef
7.
Zurück zum Zitat Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92:960–9.PubMedCrossRef Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92:960–9.PubMedCrossRef
8.
Zurück zum Zitat Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20(2):184–8.PubMedCrossRef Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20(2):184–8.PubMedCrossRef
9.
Zurück zum Zitat Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPDLys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet. 2007;175(1):47–51.PubMedCrossRef Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPDLys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet. 2007;175(1):47–51.PubMedCrossRef
10.
Zurück zum Zitat Wang LE, Gorlova OY, Ying J, et al. Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res. 2013;73(1):256–64.PubMedCrossRef Wang LE, Gorlova OY, Ying J, et al. Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res. 2013;73(1):256–64.PubMedCrossRef
11.
Zurück zum Zitat Yin J, Liang D, Vogel U, et al. The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population. Biochem Genet. 2009;47(7–8):582–90.PubMedCrossRef Yin J, Liang D, Vogel U, et al. The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population. Biochem Genet. 2009;47(7–8):582–90.PubMedCrossRef
12.
Zurück zum Zitat Long XD, Ma Y, Zhou YF, et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer. 2009;17(9):400.CrossRef Long XD, Ma Y, Zhou YF, et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer. 2009;17(9):400.CrossRef
13.
Zurück zum Zitat Lovatt T, Alldersea J, Lear JT, et al. Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Hum Mutat. 2005;25(4):353–9.PubMedCrossRef Lovatt T, Alldersea J, Lear JT, et al. Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Hum Mutat. 2005;25(4):353–9.PubMedCrossRef
14.
Zurück zum Zitat Manuguerra M, Saletta F, Karagas MR, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164(4):297–302.PubMedCrossRef Manuguerra M, Saletta F, Karagas MR, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164(4):297–302.PubMedCrossRef
15.
Zurück zum Zitat Wang M, Gu D, Zhang Z, Zhou J, Zhang Z. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health. 2009;72(11):698–705.CrossRef Wang M, Gu D, Zhang Z, Zhou J, Zhang Z. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health. 2009;72(11):698–705.CrossRef
16.
Zurück zum Zitat Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 2005;223(2):219–26.PubMedCrossRef Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 2005;223(2):219–26.PubMedCrossRef
17.
Zurück zum Zitat Özdemira N, Celkana T, Bariş S, Batarc B, Güvenc M. DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. Leuk Res. 2012;36:565–9.CrossRef Özdemira N, Celkana T, Bariş S, Batarc B, Güvenc M. DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. Leuk Res. 2012;36:565–9.CrossRef
18.
Zurück zum Zitat Dybdahl M, Vogel U, Frentz G, Wallin H, Nexø BA. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1999;8(1):77–81.PubMed Dybdahl M, Vogel U, Frentz G, Wallin H, Nexø BA. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1999;8(1):77–81.PubMed
19.
Zurück zum Zitat Sturgis EM, Zheng R, Li L, Castillo EJ, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case–control analysis. Corcinoge Anesis. 2011;21:2219–23.CrossRef Sturgis EM, Zheng R, Li L, Castillo EJ, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case–control analysis. Corcinoge Anesis. 2011;21:2219–23.CrossRef
20.
Zurück zum Zitat Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. Blood 2013. (Epub ahead of print). Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. Blood 2013. (Epub ahead of print).
21.
Zurück zum Zitat Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17(6):463–9.PubMedCrossRef Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17(6):463–9.PubMedCrossRef
22.
Zurück zum Zitat Bariş S, Celkan T, Batar B, et al. Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol. 2009;26(6):467–72.PubMed Bariş S, Celkan T, Batar B, et al. Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol. 2009;26(6):467–72.PubMed
23.
Zurück zum Zitat Shen M, Purdue MP, Kricker A, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia. Haematologica. 2007;92:1180–5.PubMedCrossRef Shen M, Purdue MP, Kricker A, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin’s lymphoma in New South Wales, Australia. Haematologica. 2007;92:1180–5.PubMedCrossRef
24.
Zurück zum Zitat Topinka J, Hertz-Picciotto I, et al. The DNA repair gene XPD/ERCC2 polymorphisms Arg156Arg (exon 6) and Lys751Gln (exon 23) are closely associated. Toxicol Lett. 2007;172(1–2):85–9.PubMedCrossRef Topinka J, Hertz-Picciotto I, et al. The DNA repair gene XPD/ERCC2 polymorphisms Arg156Arg (exon 6) and Lys751Gln (exon 23) are closely associated. Toxicol Lett. 2007;172(1–2):85–9.PubMedCrossRef
Metadaten
Titel
Excision repair cross-complementing group 2/Xeroderma pigmentousm complementation group D (ERCC2/XPD) genetic variations and susceptibility to diffuse large B cell lymphoma in Egypt
verfasst von
Mennat Allah Kamal El-Din
Mervat Mamdooh Khorshied
Zainab Ali El-Saadany
Marwa Ahmed El-Banna
Ola M. Reda Khorshid
Publikationsdatum
01.12.2013
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2013
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1462-1

Weitere Artikel der Ausgabe 6/2013

International Journal of Hematology 6/2013 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.